WASHINGTON – President Joe Biden is offering transport and logistics support to mix manufacturers and retailers to alleviate a nationwide shortage of baby formulas as the administration works to put the largest domestic plant back into operation after it was shut down earlier this year due to security issues.
The White House said it was working with all major formula manufacturers to increase production, including appealing to their suppliers to encourage them to prioritize the production and supply of formula ingredients. This comes at a time when the Biden administration has come under heavy pressure over the past week to do more to relax lack of formula which forced parents of infants to go to great lengths to feed their children.
The shortfall stems from a recall in February by Abbott, the nation’s largest formula maker, which closed the company’s Michigan plant and exacerbated current supply chain disruptions among blend manufacturers, leaving fewer options on store shelves across much of the country. The shortage has forced retailers such as CVS and Target to limit the number of containers that customers can purchase per visit, and has forced some parents to exchange and sell the mix online.
On Monday, FDA Commissioner Robert Calif told ABC News “Good Morning America” that the federal agency “is working very closely with Abbott” to rebuild a closed factory in Michigan, and he expects that ‘in a very short time we’re going to have’ a vision of the way forward. “
Caliph said that the import of infant formula from abroad will be announced, noting that the main thing is to make sure that the instructions for the mixture are contained in languages understood by mothers and caregivers.
The FDA has warned families against creating their own baby formula because it has 30 different ingredients that must be in the right amount, otherwise the mixture can be unsafe to consume.
Abbott’s voluntary recall was caused by four diseases of infants who used the powder mixture from a plant in Michigan. All four infants were hospitalized with a rare type of bacterial infection, two died.
After a six-week inspection, FDA investigators released list of problems in March, including inadequate safety standards and sanitation and a history of bacterial contamination in several parts of the plant.